University of Wisconsin, Madison: Communicable Diseases trials

The registry lists 13 Communicable Diseases studies with University of Wisconsin, Madison as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 4Phase 3 2Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)TerminatedNCT05087524Not applicableResults posted
• Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant RecipientsTerminatedNCT03617445Phase 2Results posted
• Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile InfectionCompletedNCT03462459Phase 2Results posted
• Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated PatchCompletedNCT01411891Phase 4Results posted
• Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in ChildrenCompletedNCT00593918Results posted
• MeMed BV® Test Evaluation in Adult Emergency Department PatientsCompletedNCT05706935
• BK With VST for Kidney Transplant PatientsCompletedNCT05042076Phase 1
• Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T CellsTerminatedNCT03798301Phase 1
• Immunonutrition and Carbohydrate Loading Strategies in Breast ReconstructionCompletedNCT03764943Phase 3
• Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible WomenCompletedNCT01219595Not applicable
• Meditation and Exercise for Prevention of Acute Respiratory InfectionCompletedNCT01057771Phase 2/3
• Vaccine for Recurrent Urinary Tract Infections in WomenCompletedNCT00261248Phase 2
• Nelfinavir and M8 Drug-level Monitoring in HIV-1 InfectionCompletedNCT00205283Not applicable